ABIVAX Société Anonyme (ABVX)Healthcare | Biotechnology | Paris, France | NasdaqGM
113.35 USD
-0.95
(-0.831%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 113.67 +0.32 (0.282%) ⇧ (Aug. 28, 2026, 6:01 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:57 a.m. EDT
ABVX sits at a precarious intersection of financial strength and clinical uncertainty. The balance sheet is a fortress, with nearly half a billion dollars in cash and negligible debt, yet the company burns through operating cash and reports negative returns on equity. The stock has rallied 562% over the last year, signaling intense market optimism, but it now trades below its 50-day and 200-day moving averages, suggesting a technical correction is underway. Options data confirms this tension, with sellers placing walls at $130 and $160 to cap gains, while buyers seek deep discounts at $70. For the long-term investor, the cash runway supports a wait-and-see approach, but the binary nature of biotech trials means the current valuation leaves little margin for error. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.268053 |
| MSTL | 0.275640 |
| AutoETS | 0.293685 |
| AutoTheta | 0.359598 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 0.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | 1.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.964 |
| Revenue per Share | 0.067 |
| Market Cap | 9,890,217,984 |
| Forward P/E | -36.03 |
| Beta | -0.23 |
| Website | https://www.abivax.com |
As of Aug. 22, 2026, 1:57 a.m. EDT: Speculators are positioning for upside moves toward $160-$180, evidenced by heavy call open interest at those strikes, while downside protection is concentrated at $70-$100. Deep out-of-the-money options show inflated premiums, suggesting a lottery-ticket mentality among retail traders.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.3940724 |
| Address1 | 7-11 Boulevard Haussmann |
| All Time High | 148.83 |
| All Time Low | 4.77 |
| Ask | 119.33 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 882,730 |
| Average Daily Volume3 Month | 2,021,609 |
| Average Volume | 2,021,609 |
| Average Volume10Days | 882,730 |
| Beta | -0.226 |
| Bid | 121.16 |
| Bid Size | 1 |
| Book Value | 6.3130536 |
| City | Paris |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 113.35 |
| Current Ratio | 8.247 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 115.17 |
| Day Low | 111.7229 |
| Debt To Equity | 7.964 |
| Earnings Call Timestamp End | 1,712,579,400 |
| Earnings Call Timestamp Start | 1,712,579,400 |
| Earnings Timestamp | 1,790,020,800 |
| Earnings Timestamp End | 1,790,020,800 |
| Earnings Timestamp Start | 1,790,020,800 |
| Ebitda | -254,004,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -33.583 |
| Enterprise To Revenue | 1,733.804 |
| Enterprise Value | 8,530,315,264 |
| Eps Current Year | -3.58417 |
| Eps Forward | -3.14567 |
| Eps Trailing Twelve Months | -5.34 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 123.2657 |
| Fifty Day Average Change | -9.915703 |
| Fifty Day Average Change Percent | -0.0804417 |
| Fifty Two Week Change Percent | 39.40724 |
| Fifty Two Week High | 148.83 |
| Fifty Two Week High Change | -35.480003 |
| Fifty Two Week High Change Percent | -0.23839281 |
| Fifty Two Week Low | 69.81 |
| Fifty Two Week Low Change | 43.54 |
| Fifty Two Week Low Change Percent | 0.6236929 |
| Fifty Two Week Range | 69.81 - 148.83 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,697,808,600,000 |
| Float Shares | 70,139,399 |
| Forward Eps | -3.14567 |
| Forward P E | -36.03366 |
| Free Cashflow | -114,471,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 80 |
| Fullday Change | -0.950005 |
| Fullday Change Percent | -0.83115 |
| Fullday Price | 113.67 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 4,920,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.71863 |
| Implied Shares Outstanding | 87,253,797 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-10-20 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France. |
| Long Name | ABIVAX Société Anonyme |
| Market | us_market |
| Market Cap | 9,890,217,984 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_256839883 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -332,200,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,163,822,421 |
| Number Of Analyst Opinions | 11 |
| Open | 114.34 |
| Operating Cashflow | -178,370,000 |
| Operating Margins | -41.83705 |
| Payout Ratio | 0.0 |
| Phone | 33 1 53 83 09 63 |
| Post Market Change | 0.3199997 |
| Post Market Change Percent | 0.28231117 |
| Post Market Price | 113.67 |
| Post Market Time | 1,787,954,493 |
| Previous Close | 114.3 |
| Price Eps Current Year | -31.625174 |
| Price Hint | 2 |
| Price To Book | 17.95486 |
| Price To Sales Trailing12 Months | 2,010.2069 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.072 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.950005 |
| Regular Market Change Percent | -0.83115 |
| Regular Market Day High | 115.17 |
| Regular Market Day Low | 111.7229 |
| Regular Market Day Range | 111.7229 - 115.17 |
| Regular Market Open | 114.34 |
| Regular Market Previous Close | 114.3 |
| Regular Market Price | 113.35 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 926,190 |
| Return On Assets | -0.44652 |
| Return On Equity | -1.5706799 |
| Revenue Growth | 0.352 |
| Revenue Per Share | 0.067 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 87,253,797 |
| Shares Percent Shares Out | 0.0688 |
| Shares Short | 6,001,787 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,018,322 |
| Short Name | Abivax SA |
| Short Percent Of Float | 0.0696 |
| Short Ratio | 6.39 |
| Source Interval | 15 |
| Symbol | ABVX |
| Target High Price | 187.0 |
| Target Low Price | 142.0 |
| Target Mean Price | 165.90909 |
| Target Median Price | 170.0 |
| Total Cash | 491,552,000 |
| Total Cash Per Share | 6.199 |
| Total Debt | 34,211,000 |
| Total Revenue | 4,920,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 119.23255 |
| Two Hundred Day Average Change | -5.882553 |
| Two Hundred Day Average Change Percent | -0.049336806 |
| Type Disp | Equity |
| Volume | 926,190 |
| Website | https://www.abivax.com |
| Zip | 75,009 |